STAT Plus: Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter
RUBY WALLAU FOR STAT
Zolgensma, the Novartis gene therapy for infants and the world’s most expensive medicine, continues to perform well commercially.
.png)
No hay comentarios:
Publicar un comentario